Claims for Patent: 7,879,606

Summary for Patent: 7,879,606

Title:	Compositions and methods useful for HCV infection
Abstract:	The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.
Inventor(s):	Kwong; Ann (Cambridge, MA), Byrn; Randal (Wayland, MA), Reid; Lola M (Chapel Hill, NC)
Assignee:	Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:	10/109,298
Patent Claims:	1. A composition comprising: a. a cell mixture comprising liver cells and hematopoietic cells, the cells being released from the liver of a human aged three months or older after conception up to 1 year after birth; b. a feeder cell, wherein the feeder cell is capable of providing an extracellular matrix and diffusible factors; and c. a Hepatitis C virus ("HCV"), wherein the HCV is RNA 898 ("RNA 898" deposited on Mar. 27, 2001, in the American Type Culture Collection, 10801 University Boulevard, Manassas, Va. 20110-2209; ATCC Deposit No.: PTA-3237). 2. The composition according to claim 1, wherein the cell mixture is further characterized in that said cell mixture produces more than 5,000 copies of HCV RNA seventy-two hours after administering RNA 898 to 4.times.10.sup.5 of said cells. 3. The composition according to claim 2, wherein more than 10,000 copies of HCV RNA arc produced seventy two hours after administering RNA 898. 4. The composition according to claim 2, wherein more than 50,000 copies of HCV RNA are produced seventy two hours after administering RNA 898. 5. A cell mixture comprising liver cells and hematopoietic cells, the cells being released from a liver of a human aged three months or older after conception up to 1 year after birth, wherein: each component of the cell mixture has a size that allows it to pass through a 40-micron filter; and the cell mixture also comprises cells that express alpha fetoprotein, cells that express albumin, and cells that express glycophorin, but is free of detectable cells that express CD34 protein. 6. The cell mixture according to claim 5, wherein the presence of any CD34 protein is detected by immunofluorescence or immunoperoxidase staining. 7. A composition comprising the cell mixture according to claim 5 or 6 and serum-free media, the serum-free media comprising calcium, FFAs, HDL, nicotinamidc, trace elements, EGF, insulin, transferrin and hydrocortisone and, optionally, any one of the ingredients selected from the group consisting of glucagon, liver growth factor, ethanolamine and thyrotropin releasing factor or any combination of them. 8. The composition according to claim 7, wherein the serum-free media does not comprise low density lipoprotein (LDL). 9. A composition comprising a cell mixture, serum-free media, and an HCV, the composition being prepared by the following steps: a. dissecting a liver of a human aged three months or older after conception up to 1 year after birth in a buffer comprising ethylene glycol bis(.beta.-aminoethyl ether)-N,N,N',N'-tetraacctate (EGTA); b. incubating the dissected liver in a buffer comprising collagenase to separate cells from the liver; c. passing the separated cells through a 40-micron filter; d. removing red blood cells from the filtered cells; c. resuspending the cells of step (d) in scrum-free media, comprising calcium, FFAs, HDL, nicotinamide, trace elements, EGF, insulin, transferrin, hydrocortisone, and optionally, further comprising any one of the ingredients selected from the group consisting of: glucagon, liver growth factor, ethanolamine and thyrotropin releasing factor or any combination of them; f. culturing the cells in the serum-free media of step (e); and g. infecting the cells of step (f) with an HCV. 10. The composition according to claim 9, wherein the HCV is RNA 898. 11. A composition comprising: a. a cell mixture comprising liver cells and hematopoietic cells, the cells being released from the liver of a human aged three months or older after conception up to 1 year after birth, wherein each component of the cell mixture has a size that allows it to pass through a 40-micron filter; b. an extracellular matrix; and c. an HCV, wherein the HCV is RNA 898. 12. A composition comprising: a. a cell mixture comprising liver cells and hematopoietic cells, the cells being released from the liver of a human aged three months or older after conception up to 1 year after birth, wherein each component of the cell mixture has a size that allows it to pass through a 40-micron filter; b. a feeder cell, wherein the feeder cell is capable of providing an extracellular matrix and diffusible factors; and c. an HCV, wherein the HCV is RNA 898. 13. The cell mixture according to claim 5 or 6, or the composition according to any one of claims 9, 11, and 12, wherein the cell mixture is further characterized in that said cell mixture produces more than 5,000 copies of HCV RNA seventy-two hours after administering RNA 898 to 4.times.10.sup.5 of said cells. 14. The cell mixture or the composition according to claim 13, wherein more than 10,000 copies of HCV RNA are produced seventy two hours after administering RNA 898. 15. The cell mixture or the composition according to claim 13, wherein more than 50,000 copies of HCV RNA are produced seventy two hours after administering RNA 898.

Details for Patent 7,879,606

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-03-29